ArticleScientific reports2025
Differential phenotypes in mice with smooth muscle-specific heterozygous versus homozygous deletion of Stk11.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Liver kinase B1 (Lkb1), encoded by the serine/threonine kinase gene STK11, functions as a critical tumor suppressor associated with Peutz-Jeghers syndrome (PJS). Previous studies have shown that mesenchymal-specific deletion of Stk11 promotes the development of PJS-like polyps in murine models, highlighting its essential role in mesenchymal homeostasis. In this study, we generated tamoxifen-inducible Stk11flox/flox;Myh11-Cre/ERT2 mice to achieve targeted deletion of Stk11 in mature smooth muscle cells (SMCs), allowing a comparative analysis of heterozygous versus homozygous loss-of-function phenotypes. We found that homozygous ablation of Stk11 in mature Myh11+ SMCs resulted in systemic arteriomegaly and extensive dilatation of gastrointestinal and genitourinary organs—including intestinal segments, gallbladder, ureters, and bladder. These structural abnormalities were associated with significant thinning of the muscularis propria layer and compromised tissue integrity. Interestingly, heterozygous deletion of Stk11 in mature Myh11+ SMCs fully recapitulated polyp formation characteristic of PJS, whereas complete knockout of Stk11 in these cells unexpectedly failed to induce gastrointestinal polyposis. Our results establish Stk11 as a fundamental regulator of both vascular and visceral SMC homeostasis. The genotype-dependent phenotypic divergence in SMC-specific Stk11 deficiency models underscores distinct mechanistic contributions to tissue-specific tumor suppression and PJS pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.